Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Brammer Bio Supports Rare Disease Day 2018

Brammer Bio
Posted on: 28 Feb 18

CAMBRIDGE, Mass., Feb. 28, 2018 /PRNewswire/ -- Brammer Bio ("Brammer"), a best-in-class viral vector contract development and manufacturing organization (CDMO) for cell and gene therapy companies, supports Rare Disease Day in raising awareness about rare diseases and their impact on patients' lives. Rare Disease Day is inspired to encourage our policy makers, public authorities, industry colleagues, researchers, and health professionals in efforts to address the unmet medical needs of patients with rare diseases. For more information, please visit Brammer is a sponsor and will participate in the MassBio Forum event in Boston, MA.

Mark Bamforth, CEO of Brammer, commented, "Brammer is actively engaged in supporting the development of gene therapy products for our clients and their patients.  These gene therapy products include an increasing number targeting rare diseases, as some of these treatments are demonstrating outstanding safety and efficacy.  The Brammer team consists of 350 extraordinary employees focused exclusively on serving the gene therapy needs of our clients and their patients."  Brammer offers end-to-end CDMO services from Phase 1 through commercial clinical manufacturing from our sites in Florida and Massachusetts.

The Cambridge facility in the heart of Kendall Square houses state-of-the-art equipment, with cleanroom suites specially designed to accommodate the commercial manufacturing of a broad-range of viral vector manufacturing process technologies for leading edge cell and gene therapy products. The company's 49,000 square-foot distribution center in Somerville, Massachusetts, provides high-quality storage and clinical and commercial distribution capabilities.

The Florida operations and facilities are focused on supporting early phase gene therapy clinical manufacturing capacity. 

About Brammer Bio

Brammer Bio provides clinical and commercial supply of viral vectors for in vivo gene and ex vivo modified-cell based therapies, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders and all employees. For more information, please visit

About Ampersand Capital Partners

Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Visit

Brammer Bio:
13859 Progress Boulevard
Alachua, FL 32615

250 Binney Street
Cambridge, MA 02142 

Sales Enquiries: +1 866 GENE CMO (436 3266) 

Editor's Details

Mike Wood

Last updated on: 28/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.